期刊文献+

联合抗Fas核酶和CD80-免疫球蛋白G融合蛋白阻断小鼠急性粒-单核白血病细胞逃逸T细胞杀伤 被引量:1

Blocking the escape of leukemic cells from killing of T cell by combining anti-Fas ribozyme and CD80-IgG fusion protein
原文传递
导出
摘要 目的研究抗Fas锤头状核酶下调细胞毒T细胞(CTL)的Fas表达,以及CD80-免疫球蛋白G(CD80-IgG)融合蛋白增加急性粒-单核白血病细胞表面的CD80分子表位对CTL杀伤急性粒-单核白血病细胞能力的影响。方法构建可有效切割Fas mRNA的锤头状核酶真核质粒,通过电穿孔法导入小鼠脾脏T细胞,逆转录-聚合酶链反应(RT-PCR)和Western印迹检测T细胞Fas的表达;同时构建pcDNA/CD80-IgG融合基因真核表达载体,采用脂质体技术导入中国地仓鼠卵巢细胞株(CHO)细胞中,并采用免疫亲和层析法纯化CHO细胞上清中的CD80-IgG融合蛋白,用其孵育急性粒-单核白血病细胞株(WEHI-3)后,与上述转染Fas mRNA锤头状核酶的T细胞进行同种异体白血病细胞和淋巴细胞混合培养;膜联蛋白V-异硫氰酸荧光素(FITC)检测T细胞凋亡率,四甲基偶氮唑蓝微量反应比色法(MTT法)检测T细胞增殖和CTL体外杀伤WEHI-3细胞的能力。结果凝胶图像分析小鼠脾脏T细胞Fas蛋白电泳条带的灰度比值显示以对照组为1,空载体(pEGFPC1)和Fas核酶RZ596重组真核表达载体(pEGFP-RZ596)转染组分别为0.98和0.45(P<0.01);当转染pEGFP-RZ596的小鼠脾脏T细胞与高表达Fas配体的(64%±3%)WEHI-3细胞混合培养后,T细胞凋亡率为37%,对WEHI-3细胞的杀伤活性为67%,而对照及转染pEGFPC1小鼠脾脏T细胞组的凋亡率和对WEHI-3细胞的杀伤活性分别为88%、84%(P<0.01)和32%、31%(P<0.01)。WEHI-3细胞表面CD80表达率仅为5.1%±0.4%,经CD80-IgG融合蛋白预孵育后增至27.4%±2.2%(P<0.01);小鼠脾脏T细胞对CD80-IgG融合蛋白预孵育和未孵育的WEHI-3细胞杀伤率分别为64%和49%(P<0.01)。转染Fas核酶的小鼠脾脏T细胞对CD80-IgG融合蛋白预孵育的WEHI-3细胞杀伤率增至82%(P<0.01)。结论联合抗Fas核酶和CD80-IgG融合蛋白能使小鼠CTL免于FasL-Fas途径的凋亡;并显著增强其杀伤急性粒单核白血病细胞的效应。 Objective To study Fas expression regulation of cytotoxic T lymphocyte(CTL) via anti-Fas ribozyme, increasing of CD80 epitope on the surface of acute myelomonocytic leukemia cells by CD80-IgG fusion protein and their effects on the apoptosis and killing ability against acute myelomonocytic leukemia cells of CTL. Methods A hammerhead ribozyme gene targeting the Fas mRNA was synthesized and its expression vector pEGFP-RT596 was constructed and transfected into the mouse spleen T cells via electroporation. The Fas expression on T cells was detected by RT-PCR and Western bloting. In the meantime the eukaryotic expression vector pcDNA/CD80-IgG was constructed by gene recombinant technique and transfected into ovarian cells of hamster of the line CHO. The CD80-IgG fusion protein was purified from the supernatant of G418-selected CHO cells by Protein G affinity chromatography method. Then allogeneic mixed lymphocytes culture between the mouse spleen T cells transfected with pEGFP-RZ96 and WEHI-3 cells( mouse acute myelomonocyte leukemia cell line ) incubated with CD80-IgG fusion protein was performed. The apoptosis rate of the T cells was detected with annexinV-FITC. The proliferation and killing ability in vitro against WEHI-3 cells of the T cells were detected by MrlT colorimetry. Results The luminance of Fas Western bloting results from the mouse spleen T cells negative control, transfected with pEGFPC1 and transfected with pEGFP-RZ96 were separately 1,0.98 and 0.45 ( P 〈 0.01 ). After being cocultured with WEHI-3 cells, which has higher expression of Fas ligand (64% ± 3% ) , the apoptosis rate and the killing ability against WEHI-3 cells of the mouse spleen T cells transfected with pEGFP-RZ96 were separately 37% and 67%. Whereas that of the mouse spleen T cells negative control and transfected with pEGFPC1 were separately 88% ,84% ( P 〈 0.01 ) and 32% ,31% ( P 〈 0.01 ). The CD80 positive expression rate of WEHI-3 cells was upregulated from 5. 1% ± 0.4% to 27.4% ± 2. 2% after these cells were preincubated with CD80-IgG fusion protein ( P 〈 0.01 ). The killing ability of the mouse spleen T cells against WEHI-3 cells preincubated and not preincubated with CD80-IgG fusion protein were separately 64% and 49% ( P 〈 0.01 ), but that of the mouse spleen T cells, which were transfected with pEGFP-RT^96, was further promoted to 82% ( P 〈 0.01 ) Conclusion The apoptosis of mouse CTL inducing by FasL-Fas pathway could be avoided and the killing ability of mouse CTL against WEHI-3 cells can be significantly promoted at the same time by combining anti-Fas ribozyme and CD80-IgG fusion protein.
出处 《中华医学杂志》 CAS CSCD 北大核心 2005年第49期3469-3474,共6页 National Medical Journal of China
基金 国家自然科学基金资助项目(30240022)
关键词 重组融合蛋白质类 T淋巴细胞 细胞毒性 免疫逃逸 急性粒-单核白血病细胞 抗Fas锤头状核酶下调细胞毒T细胞 Recombinant fusion proteins T-lymphocyte cytotoxic Leukemia, monocytic acute Immune escape
  • 相关文献

参考文献1

二级参考文献22

  • 1Chen C C.查看详情,1993.
  • 2Yu X;Abe R;Hodes RJ.The role of B7-CD28 costimulation in tumor rejection[J],1998(6).
  • 3Bretscher P.The two-signal model of lymphocyte activation twenty-one years later[J],1992.
  • 4Linsley PS;Greene JL;Tan P.Coexpression and founctional cooperation of CTLA-4 and CD28 on activated T lymphocytes[J],1992.
  • 5Jun CH;Bluestone JA;Nadler LM.The B7 and CD28 receptor families[J],1994.
  • 6Harding FA;McArthur JG;Gross JA.CD28-mediated signaling costimulates murine T cells and prevents induction of anergy in T-cell clones[J],1992.
  • 7Boussiotis VA;Freeman GJ;Gray G.B7 but not intercellular adhesion molecule-1 co-stimulation prevents the induction of human alloantigen-specific tolerance[J],1993.
  • 8Heuer JG;Tucker-McClung C;Gonin R.Retrovirus mediated gene transfer of B7-1 and MHC class Ⅱ converts a poorly immunogenic neuroblastoma into a highly immunogenic one[J],1996(07).
  • 9Stremmel C;Greenfield EA;Howard E.B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by interleukin 4-dependent mechanism[J],1999.
  • 10Moro M;Gasoarri AM;Paganoi S.Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules[J],1999.

共引文献9

同被引文献10

  • 1刘程伟,胡新华,杨军,张强,张雪松,段志泉.早期生长反应基因-1及其相关基因在大鼠自体移植静脉中的表达及意义[J].中华医学杂志,2005,85(48):3414-3418. 被引量:2
  • 2Schubert S,Kurreck J.Ribozyme-and deoxyribozyme-strategies for medical applications.Curr Drug Targets,2004,5:667-681.
  • 3Citti L,Rainaldi G.Synthetic hammerhead ribozymes as therapeutic tools to control disease genes.Curr Gene Ther,2005,5:11-24.
  • 4Weng DE,Masci PE,Radka SF,et al.A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.Mol Cancer Ther,2005,4:948-955.
  • 5Takagi Y,Suyama E,Kawasaki H,et al.Mechanism of action of hammerhead ribozymes and their applications in vivo:rapid identification of functional genes in the post-genome era by novel hybrid ribozyme libraries.Biochem Soc Trans,2002,30:1145-1149.
  • 6Penchovsky R,Breaker RR.Computational design and experimental validation of oligonucleotide-sensing allosteric ribozymes.Nat Biotechnol,2005,23:1424-1433.
  • 7Akowuah EF,Sheridian PJ,Cooper GJ,et al.Preventing saphenous vein graft failure:does gene therapy have a role? Ann Thorac Surg,2003,76:959-966.
  • 8Leask RL,Butany J,Johnston KW,et al.Human saphenous vein coronary artery bypass graft morphology,geometry and hemodynamics.Ann Biomed Eng,2005,33:301-309.
  • 9Wang Z,Castresana MR,Detmer K,et al.An IkappaB-alpha mutant inhibits cytokine gene expression and proliferation in human vascular smooth muscle cells.J Surg Res,2002,102:198-206.
  • 10Blackwell TS,Christman JW.The role of nuclear factor-kappa B in cytokine gene regulation.Am J Respir Cell Mol Biol,1997,17:3-9.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部